Sign Up to like & get
recommendations!
1
Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.6_suppl.102
Abstract: 102Background: In ARCHES (NCT02677896) ENZA + ADT reduced the risk of radiographic progression-free survival (rPFS) events, primary endpoint, and improved key secondary endpoints vs PBO + ADT in me...
read more here.
Keywords:
progression;
efficacy enzalutamide;
enza plus;
mhspc ... See more keywords